Raymond James & Associates’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Raymond James & Associates’s Portfolio SGNT Stock Details SGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-184,747	Closed	-$2.77M	–	3366
2016 Q2	$2.77M	Buy	184,747 +36,872	+25%	+$474K	0.01%	1147
2016 Q1	$1.8M	Sell	147,875 -522	-0.4%	-$7.32K	0.01%	1331
2015 Q4	$2.36M	Buy	148,397 +18,620	+14%	+$293K	0.01%	1179
2015 Q3	$1.99M	Sell	129,777 -2,058	-2%	-$44.5K	0.01%	1215
2015 Q2	$3.21M	Buy	+131,835	New	+$3.16M	0.01%	1054

Raymond James & Associates's SGNT Position: Q3 2016 in Review

Raymond James & Associates sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 184,747 shares — an estimated $2.77M sold.

Raymond James & Associates first reported a position in SGNT in Q2 2015 and held it in 5 quarters. The position peaked at $3.21M in Q2 2015. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.

Raymond James & Associates reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
Raymond James & Associates sold 184,747 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $2.77M.
Raymond James & Associates first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2015 and held it in 5 quarters.
Raymond James & Associates's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $3.21M in Q2 2015.
0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.

Based on Raymond James & Associates's 13F filing for Q3 2016, filed 14 Nov 2016.